Jetrea FDA Approval History
FDA Approved: Yes (First approved October 17, 2012)
Brand name: Jetrea
Generic name: ocriplasmin
Dosage form: Intravitreal Injection
Company: ThromboGenics NV
Treatment for: Vitreomacular Adhesion
Jetrea (ocriplasmin) is a proteolytic enzyme indicated for the treatment of symptomatic vitreomacular adhesion.
Development timeline for Jetrea
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.